ABUS vs BROS · P/E 5.4, rev $6.2M vs P/E 105, rev $1.28B
Arbutus Biopharma Corp (ABUS) versus Dutch Bros Inc (BROS) — a side-by-side from cached financials, not a winner call.
Arbutus Biopharma Corp (ABUS) is a biotechnology company listed on NASDAQ.
Dutch Bros Inc (BROS) is a restaurants company listed on NYSE.
Latest reported ABUS revenue for 2024-12-31 was $6.2M. Net income was -$69.9M. Revenue was down 66.0% from 2023-12-31 to 2024-12-31. ABUS currently screens at market cap $883.0M and trailing P/E 5.4.
Latest reported BROS revenue for 2024-12-31 was $1.28B. Net income was $66.5M. Revenue was up 32.6% from 2023-12-31 to 2024-12-31. BROS currently screens at market cap $11.74B and trailing P/E 105.0.
ABUS currently screens at market cap $883.0M and trailing P/E 5.4. BROS currently screens at market cap $11.74B and trailing P/E 105.0.
Not investment advice. Open the ABUS and BROS stock pages for the full models.
Not investment advice.